CAS：1018899-04-1
Sopagliflozin LX-4211 is a dual inhibitor of SGLT1/SGLT2 and has a brand-new hypoglycemic mechanism. Existing studies have proved that it is effective for both type 1 diabetes and type 2 diabetes. In three key multicenter Phase III clinical studies of sopagliflozin as an insulin-adjuvant therapy for type 1 diabetes, the sopagliflozin group achieved the endpoints of the trials in all cases, and no severe hypoglycemia or other SAEs occurred during the study period. This provides a clinical basis for the approval of sopagliflozin as an insulin-assisted therapy for type 1 diabetes.